You are here: Industry Insights > Market News > Govt aims to raise API production to cut Chinese dependence

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

PVP-K30-----pharma excipients(CAS No.9003-39-8)

Tobramycin

Povidone iodine 20% powder

Povidone iodine 10% powder

SULBACTAM SODIUM STERILE

Food Additives Bulk Sucralose Neotame Advantame Powder

Govt aims to raise API production to cut Chinese dependence

expressbpdOctober 11, 2018

Tag: china , API , pharma

Favorites

The government is working on a road map to increase production of bulk drugs in the country with a view to reduce import dependence of the raw materials for pharma sector from China, a commerce ministry report said.

Previous:Agios receives nod for ivosidenib

Next:Allergan works toward blockbuster goal with new CoolSculpting OK

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

PharmaSourcesSeptember 19, 2024

InnoCare Pharma announced today the approval of the Investigational New Drug (IND) to conduct the clinical trial of B-cell lymphoma-2 (BCL2) inhibitor ICP-248 in combination with azacitidine for acute myeloid leukemia (AML) in China.

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

PharmaSourcesSeptember 18, 2024

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

PharmaSourcesSeptember 14, 2024

Govt aims to raise API production to cut Chinese dependence | Pharmasources.com

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

Biotech NewswireAugust 28, 2024

Currax Pharmaceuticals LLC announced the results of a Cardiovascular Health Outcomes Analysis.The results showed there is no evidence of excess cardiovascular risk.

You may like
More>>

trimethoprim lactate Veterinary supply in China GMP

VHP pass box used in pharmaceutical industry

Stevioside STV series,R-A series supplier Sweeteners Food Additive made in china

Quetiapine Fumarate

chamomile extract/ chamomile flower extract/ nature Apigenin good quality with free sample

Vertical Type Fluidizing Dryer in Pharmaceutical

L-Citrulline AJI92/97 Amino acid made in china

Silodosin other active pharmaceutical ingredients

Pharmaceutical industry GMP plant

China Flu Shots-Hualan Bio

Govt aims to raise API production to cut Chinese dependence

Related News

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China

Cordlife Unveils Enhanced Processing and Storage Facility in Singapore; Strengthens Processes as It Resumes Collection of Cord Blood Units in a Controlled Manner

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024

Currax Pharmaceuticals: CONTRAVE®/MYSIMBA® Demonstrates Positive Cardiovascular Safety in a Large, Real-World Evidence Study

You may likeMore>>

You may like
More>>